Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01077388
Other study ID # 2R01HL075263-05
Secondary ID
Status Completed
Phase Phase 3
First received February 25, 2010
Last updated October 11, 2017
Start date May 2010
Est. completion date August 2012

Study information

Verified date October 2017
Source Kaiser Permanente
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The e-Care for Heart Wellness study will look at ways to reduce a person's chances of getting heart disease. We are asking about 100 Group Health members whose electronic medical record shows they have uncontrolled high blood pressure to be in the study. Having high blood pressure increases your future risk of heart attacks and strokes.

There are many things you can do to help keep your heart healthy. Examples include lowering blood pressure and cholesterol, eating healthier, and being more active. Our goal is to test whether getting care and supportive emails from a dietician helps people do things like this to lower their chances of having a heart attack or a stroke.

For some people, this study will involve both research and clinical care. About half the people in the study will receive care related to heart disease prevention from a dietician. It's a standard clinical practice for dieticians to help people reduce their risk of heart attacks and strokes. What's different about this study is using emails from a dietician to help people take steps to improve their heart health.


Description:

Overweight and obese adults are more likely to have hypertension and other risk factors for cardiovascular disease (CVD). Evidence-based medication and lifestyle strategies exist for reducing CVD risk, but little is known about the comparative effectiveness and cost-effectiveness of these strategies and how best to integrate them into routine health care. We have previously demonstrated that Web-based pharmacist medication management intervention can cost-effectively improve HTN control (e-BP: Electronic Communication and Home Blood Pressure Monitoring; R01 HL075263, B. Green, PI). Web-based pharmacy care did not lead to lifestyle behavior change or weight loss. However patients who lost small amounts of weight (2 kg or more) were more likely to have controlled BP (p=.008), regardless of their study group assignment. We propose using Health Information Technology systems (HIT) to identify asymptomatic patients at moderate risk for CVD and invite them to participate in a theory-based behavioral intervention that uses the Chronic Care Model as its planning foundation.

Specific Aims Aim #1: We hypothesize that using electronic databases alone, we can identify asymptomatic overweight or obese patients, with uncontrolled BP, and at moderate risk for CVD who might benefit from a behavioral intervention.

Aim #2: We hypothesize that a dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, can be integrated into routine healthcare and will result in improved control of modifiable CVD risk. To test this hypothesis we will measure:

Primary outcomes:

1. The proportion of patients who agree to participate and complete the intervention.

2. The change in mean systolic and diastolic BP and weight (kg), and a weight loss of 4 kg or more, and the change in Framingham risk score.

Secondary outcomes:

1. Patient satisfaction with the intervention, its effects on health related quality of life (HrQOL) and the cost of delivering the intervention.

Using this information and the results of the e-BP trial we will plan a full scale, multi-site (2-3 health institutions with comprehensive EMR's and different geographic and patient populations) multi-factorial randomized trial—to test the comparative effectiveness of different strategies to improve control of modifiable CVD risk.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date August 2012
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender All
Age group 30 Years to 69 Years
Eligibility Inclusion Criteria:

- All adults age 30-<70 men and women who have received care at GH primary care medical centers in Western Washington and who have been continuously enrolled in GH for at least 2 years.

- BMI 26 or higher,

- Uncontrolled HTN (based on the 2 most recent visits), and moderate risk for CVD.

Exclusion Criteria:

- A history of any type of cardiovascular disease (CVD). Including TIA, stroke, coronary heart disease (CHD), angina, congestive heart failure (CHF), peripheral arterial disease (PAD), ar, CHF, PAD), arrhythmias, cardiomyopathy, and valvular disease.

- Pre existing diagnosis of diabetes

- Diagnosis of a serious life threatening or limiting condition

- Pre existing diagnosis of alcohol or chemical dependency

- Pregnant or planning on becoming pregnant in the next 6 months. Women randomized to the intervention group who become pregnant during the study will be given the option of continuing the intervention in conjunction with usual pre-natal care provided by GH, but will not be included in the final analysis for the study. Women randomized to the self care group who become pregnant during the study will be given the home monitoring equipment usually given to the control group at the end of the study. They will then be referred for usual care and will also not be included in the final analysis for the study.

- Unable or unwilling to participate

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Dietician electronic support
Dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, will be integrated into routine healthcare and will result in improved control of modifiable CVD risk.

Locations

Country Name City State
United States Group Health Cooperative Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Kaiser Permanente National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT02480504 - Effects of a 5:2 Diet on Weight Loss and Cardiovascular Risk Factors in Obesity N/A
Completed NCT02440893 - Understanding the Effect of Metformin on Corus CAD (or ASGES)
Completed NCT01486030 - Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
Active, not recruiting NCT00038727 - Diabetes Prevention Program Outcomes Study Phase 3
Completed NCT03967678 - Omega (n)-3 PUFA Enriched Beef & Health Outcomes. N/A
Completed NCT01251302 - Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern
Not yet recruiting NCT05716659 - EEG/MECG/EMG Evaluating the Severity of Aortic Stenosis, Heart Failure and Ischemic Stroke Through an Artificial Intelligenceassisted System.
Withdrawn NCT02158754 - Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making
Completed NCT04384029 - The Geneva Covid-19 CVD Study
Active, not recruiting NCT02382822 - Copenhagen Co-morbidity in HIV Infection Study
Active, not recruiting NCT01825668 - Effect of Plant Sterol Enriched Milk on Plasma Lipid Levels of Humans Breast-fed During Infancy N/A
Completed NCT02223286 - Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making N/A
Completed NCT00289237 - Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease N/A
Not yet recruiting NCT03658031 - Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction Phase 3
Completed NCT03636529 - Tart Cherry Juice and Markers of Inflammation, CVD, and Diabetes N/A
Completed NCT00500617 - Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
Completed NCT00500708 - Diagnostic Investigation of Sudden Cardiac Event Risk N/A
Completed NCT01255852 - Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting Phase 4
Completed NCT00583297 - Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial N/A
Completed NCT02405754 - Clinical Utility of an Age, Sex, and Gene Expression Score (ASGES or Corus CAD) in African American Patients.